New hope for kids with brain cancer: triple therapy trial launches
NCT ID NCT07017816
First seen Apr 29, 2026 · Last updated May 17, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug (SGT-53) combined with radiation and immunotherapy (Nivolumab) in up to 18 children whose brain tumors have returned or not responded to standard treatments. The main goal is to find a safe dose and understand side effects. It is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PINEOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.